Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32969947.
- Also identified by DOI 10.14309/ajg.0000000000000935 and PMC identifier 8263231.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the upper gastrointestinal (UGI) cancer risk and surveillance outcomes in Li-Fraumeni syndrome (LFS). Analysis of the International Agency for Research on Cancer database and a single-center adult LFS cohort. UGI cancer was present in 7.2% of families and 3.9% of individuals with a pathogenic/likely pathogenic TP53 mutation in International Agency for Research on Cancer; 29% occurred before age 30. Our institutional cohort had 35 individuals (31% of the LFS cohort) with 48 cumulative upper endoscopies; 3 (8.5%) individuals had concerning UGI findings. UGI cancer is observed in LFS. Upper endoscopy should be part of a comprehensive LFS surveillance program.
Medical subject headings
- Adolescent
- Adult
- Aged
- Esophageal Neoplasms/etiology
- Esophageal Neoplasms/genetics
- Female
- Genetic Predisposition to Disease
- Germ-Line Mutation
- Humans
- Li-Fraumeni Syndrome/complications
- Li-Fraumeni Syndrome/genetics
- Male
- Middle Aged
- Risk Factors
- Stomach Neoplasms/etiology
- Stomach Neoplasms/genetics
- Tumor Suppressor Protein p53/genetics
- Young Adult